Apogee Therapeutics, Inc. Share Price & Technical Analysis
APGE · $90.90 (+7.97%)
Healthcare / Biotechnology
$90.90
+7.97%
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatm…
Price chart
Seasonality
Jun has 2 positive and 1 negative years (last 4 years shown)
13% return in Jun, 1% avg return in past 3 year Jun month.
30% return in 2026, 64% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -14% | 11% | 25% | -3% | -2% | 13% | – | – | – | – | – | – | 30% |
| 25 | -10% | -22% | 14% | 6% | -6% | 17% | -11% | -3% | 9% | 43% | 26% | 5% | 69% |
| 24 | 22% | 2% | 91% | -24% | -10% | -15% | 24% | 5% | 15% | -11% | -13% | -1% | 84% |
| 23 | – | – | – | – | – | – | 0% | 8% | -7% | -19% | 14% | 45% | 40% |
Monthly return % by calendar month · historical pattern, not a forecast
Strong Momentum · Strong · Strong
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$5.98B
P/E ratio
—
52W high
$95.31
52W low
$34.34
Volume
14,34,905
Beta
0.69
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹34,400
Abbott Laboratories Cede…
₹32,740
Eli Lilly And Company Ce…
₹28,720
Unitedhealth Group Inc C…
₹17,140
Elevance Health Inc
₹6,770
Frequently asked questions
- What is Apogee Therapeutics, Inc. share price today?
- Apogee Therapeutics, Inc. (APGE) last traded around $90.90 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does APGE have?
- StockPro currently tracks 1 active signal(s) for APGE, including breakouts, momentum, and volume patterns. See the signals panel on this page.
- How can I analyze Apogee Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.